Area of research
Cardiology and Cardiovascular Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Acute Myocardial Infarction Research, Cardiac Imaging and Diagnostics, Coronary Interventions and Diagnostics, and Antiplatelet Therapy and Cardiovascular Diseases.
Machine learning to risk stratify individuals for undiagnosed atrial fibrillation at scale using population-wide electronic health records.
Effect of Cumulative Blood Pressure Exposure on Long-Term Cardiovascular Outcomes in the Community, a Nationwide Cohort Study
Impact of Admission Ward on Long-Term Outcomes in Patients with Non-ST Elevation Myocardial Infarction.
Takotsubo Cardiomyopathy During Armed Conflict: A Case Series
Takotsubo Cardiomyopathy during Armed Conflict: A Case Series
Prediction Models for Heart Failure in the Community: A Systematic Review and Meta-Analysis
Routine troponin testing before non-cardiac surgery: does the evidence justify the consequences?
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Peripheral Arterial Disease in Patients With Acute Coronary Syndrome: Results From a Large Real-World Registry
Acute myocardial infarction in the Covid-19 era: Incidence, clinical characteristics and in-hospital outcomes—A multicenter registry
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Diagnosis and risk stratification of chest pain patients in the emergency department: focus on acute coronary syndromes. A position paper of the Acute Cardiovascular Care Association
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial
European Society of Cardiology: Cardiovascular Disease Statistics 2019
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial